Table of Contents

1 Study Coverage

• 1.1 β-blockers Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global β-blockers Market Size Growth Rate by Product
  • 1.4.2 Nonselective Agents
  • 1.4.3 Selective Agents
• 1.5 Market by End User
  • 1.5.1 Global β-blockers Market Size Growth Rate by End User
  • 1.5.2 Abnormal Heart Rhythms
  • 1.5.3 Hypertension
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global β-blockers Market Size
  • 2.1.1 Global β-blockers Revenue 2014-2025
  • 2.1.2 Global β-blockers Sales 2014-2025
• 2.2 β-blockers Growth Rate by Regions
  • 2.2.1 Global β-blockers Sales by Regions
  • 2.2.2 Global β-blockers Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 β-blockers Sales by Manufacturers
  • 3.1.1 β-blockers Sales by Manufacturers
  • 3.1.2 β-blockers Sales Market Share by Manufacturers
  • 3.1.3 Global β-blockers Market Concentration Ratio (CR5 and HHI)
• 3.2 β-blockers Revenue by Manufacturers
  • 3.2.1 β-blockers Revenue by Manufacturers (2014-2019)
  • 3.2.2 β-blockers Revenue Share by Manufacturers (2014-2019)
• 3.3 β-blockers Price by Manufacturers
• 3.4 β-blockers Manufacturing Base Distribution, Product Types
  • 3.4.1 β-blockers Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers β-blockers Product Type
  • 3.4.3 Date of International Manufacturers Enter into β-blockers Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global β-blockers Sales by Product
• 4.2 Global β-blockers Revenue by Product
• 4.3 β-blockers Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global β-blockers Breakdown Data by End User

6 North America

• 6.1 North America β-blockers by Countries
  • 6.1.1 North America β-blockers Sales by Countries
  • 6.1.2 North America β-blockers Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America β-blockers by Product
• 6.3 North America β-blockers by End User

7 Europe

• 7.1 Europe β-blockers by Countries
  • 7.1.1 Europe β-blockers Sales by Countries
  • 7.1.2 Europe β-blockers Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe β-blockers by Product
• 7.3 Europe β-blockers by End User

8 Asia Pacific

• 8.1 Asia Pacific β-blockers by Countries
  • 8.1.1 Asia Pacific β-blockers Sales by Countries
  • 8.1.2 Asia Pacific β-blockers Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific β-blockers by Product
• 8.3 Asia Pacific β-blockers by End User

9 Central & South America

• 9.1 Central & South America β-blockers by Countries
  • 9.1.1 Central & South America β-blockers Sales by Countries
  • 9.1.2 Central & South America β-blockers Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America β-blockers by Product
• 9.3 Central & South America β-blockers by End User

10 Middle East and Africa

• 10.1 Middle East and Africa β-blockers by Countries
  • 10.1.1 Middle East and Africa β-blockers Sales by Countries
  • 10.1.2 Middle East and Africa β-blockers Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa β-blockers by Product
• 10.3 Middle East and Africa β-blockers by End User

11 Company Profiles

• 11.1 Pfizer
  • 11.1.1 Pfizer Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Pfizer β-blockers Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Pfizer β-blockers Products Offered
  • 11.1.5 Pfizer Recent Development
• 11.2 Novartis
  • 11.2.1 Novartis Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Novartis β-blockers Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Novartis β-blockers Products Offered
  • 11.2.5 Novartis Recent Development
• 11.3 Merck
  • 11.3.1 Merck Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Merck β-blockers Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Merck β-blockers Products Offered
  • 11.3.5 Merck Recent Development
• 11.4 Astra Zeneca
  • 11.4.1 Astra Zeneca Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Astra Zeneca β-blockers Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Astra Zeneca β-blockers Products Offered
  • 11.4.5 Astra Zeneca Recent Development
• 11.5 Jhonson and Johnson
  • 11.5.1 Jhonson and Johnson Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Jhonson and Johnson β-blockers Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Jhonson and Johnson β-blockers Products Offered
  • 11.5.5 Jhonson and Johnson Recent Development
• 11.6 Eli Lilly
  • 11.6.1 Eli Lilly Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Eli Lilly β-blockers Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Eli Lilly β-blockers Products Offered
  • 11.6.5 Eli Lilly Recent Development
• 11.7 Sanofi
  • 11.7.1 Sanofi Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Sanofi β-blockers Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Sanofi β-blockers Products Offered
  • 11.7.5 Sanofi Recent Development
• 11.8 Bristol-Myers Squibb
  • 11.8.1 Bristol-Myers Squibb Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Bristol-Myers Squibb β-blockers Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Bristol-Myers Squibb β-blockers Products Offered
  • 11.8.5 Bristol-Myers Squibb Recent Development
• 11.9 Bayer
  • 11.9.1 Bayer Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Bayer β-blockers Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Bayer β-blockers Products Offered
  • 11.9.5 Bayer Recent Development
• 11.10 GSK
  • 11.10.1 GSK Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 GSK β-blockers Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 GSK β-blockers Products Offered
  • 11.10.5 GSK Recent Development
• 11.11 Teva Pharmaceutical

12 Future Forecast

• 12.1 β-blockers Market Forecast by Regions
  • 12.1.1 Global β-blockers Sales Forecast by Regions 2019-2025
  • 12.1.2 Global β-blockers Revenue Forecast by Regions 2019-2025
• 12.2 β-blockers Market Forecast by Product
  • 12.2.1 Global β-blockers Sales Forecast by Product 2019-2025
  • 12.2.2 Global β-blockers Revenue Forecast by Product 2019-2025
• 12.3 β-blockers Market Forecast by End User
• 12.4 North America β-blockers Forecast
• 12.5 Europe β-blockers Forecast
• 12.6 Asia Pacific β-blockers Forecast
• 12.7 Central & South America β-blockers Forecast
• 12.8 Middle East and Africa β-blockers Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 β-blockers Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

β-blockers are a class of medications that are predominantly used to manage abnormal heart rhythms, and to protect the heart from a second heart attack (myocardial infarction) after a first heart attack (secondary prevention). They are also widely used to treat high blood pressure (hypertension), although they are no longer the first choice for initial treatment of most patients.
The global β-blockers market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the β-blockers market based on company, product type, end user and key regions.

This report studies the global market size of β-blockers in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of β-blockers in these regions.
This research report categorizes the global β-blockers market by top players/brands, region, type and end user. This report also studies the global β-blockers market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical

Market size by Product
Nonselective Agents
Selective Agents
Market size by End User
Abnormal Heart Rhythms
Hypertension

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global β-blockers market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of β-blockers market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global β-blockers companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of β-blockers submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of β-blockers are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of β-blockers market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.